版本:
中国

BRIEF-Acasti Pharma provides update on Capre phase 3 development program

March 30 Acasti Pharma Inc

* Acasti Pharma provides update on Capre phase 3 development program

* Plans to proceed with its phase 3 development program for Capre

* Acasti Pharma Inc - outcome of end-of-phase 2 meeting with FDA confirms phase 3 program is on track to start late 2017

* Acasti Pharma- plans to conduct 2 pivotal, randomized, placebo controlled studies to evaluate efficacy, safety of Capre in patients with hypertriglyceridemia Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐